Chronic Myeloid Leukaemia (CML) – Updates from the European Haematology Association Conference

In June, our team attended the European Haematology Association (EHA) conference. Here they share the latest updates about Chronic Myeloid Leukaemia (CML).

Our campaigns and advocacy team attended the European Haematology Association conference in June to hear the latest news from research, clinical trials and clinical practice. Here are the latest updates in CML, with videos from the clinicians attending the conference.

The main CML topics at the conference were:

  • Treatment Free Remission (TFR)

TFR is a process of stopping treatment with TKI drugs and the level of leukaemia cells remaining at very low/undetectable levels. A lot of data on trials was presented at the conference, showing that it is safe to attempt TFR under certain conditions and evidence shows that around half of people who stop their treatment will achieve TFR.

  • New CML therapies

While the emergence of TKI drugs has been incredibly successful in treating and managing CML, the side effects that patients experience are often quite difficult to live with.

Research is ongoing into novel CML therapies that are as successful at treating CML but also have fewer side effects associated with them.

Hear the highlights from clinicians at the conference, including Timothy Hughes from the Royal Adelaide Hospital in Australia.

View more videos from the conference by visiting our YouTube page here.

Coping with bereavement

For most of us, losing a loved one can be devastating and lonely. Grief is what you will normally experience when somebody you are close to dies and it affects people in different ways.

Read More